Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03712202
Title Brentuximab Vedotin and Nivolumab in Treating Participants With Early Stage Classic Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors City of Hope Medical Center
Indications

Hodgkin's lymphoma

Hodgkin's lymphoma, nodular sclerosis

Hodgkin's lymphoma, lymphocytic depletion

Hodgkin's lymphoma, lymphocytic-histiocytic predominance

Hodgkin's lymphoma, mixed cellularity

Therapies

Nivolumab

Brentuximab vedotin + Nivolumab

Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine

Bleomycin + Dacarbazine + Doxorubicin + Vinblastine

Age Groups: child | adult | senior
Covered Countries USA


No variant requirements are available.